During the past decade, Ohio State University; B406 Starling-Loving Hall conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Ohio State University; B406 Starling-Loving Hall" are "Diffuse Large B-Cell Lymphoma" (1 trials) and "Non-Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Ohio State University; B406 Starling-Loving Hall" in a lesser frequency.

Most popular intervention types in "Ohio State University; B406 Starling-Loving Hall" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Cyclophosphamide" (1 trials), "Doxorubicin" (1 trials), "Polatuzumab Vedotin" (1 trials) and "Polatuzumab vedotin Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ohio State University; B406 Starling-Loving Hall" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Ohio State University; B406 Starling-Loving Hall". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Ohio State University; B406 Starling-Loving Hall, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Ohio State University; B406 Starling-Loving Hall, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".